IP Library Patent Application 11714301
Patent Application
App. No. 11/714,301

Method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/714,301
Abstract

The invention provides a method to effectively wean a woman from hormonal therapy for treatment of vasomotor symptoms by reducing the dosage of the hormonal agent to zero, while a non-hormonal drug in an amount, which is therapeutically effective for treating vasomotor symptoms, is administered or initiated and continued for one or more periods of durations determined by assessment of the effect of a treatment free period, which follows each period of continuous non-hormonal drug treatment.

Claims (7)

1 . A method to effectively wean a woman from hormonal therapy for treatment of vasomotor symptoms by reducing the dosage of the hormonal agent to zero, while a non-hormonal drug in an amount, which is therapeutically effective for treating vasomotor symptoms, is administered or initiated and continued for one or more periods of durations determined by assessment of the effect of a treatment free period, which follows each period of continuous non-hormonal drug treatment.

2 . The method according to claim 1 , wherein the non-hormonal drug is S-mirtazapine or a salt thereof.

3 . The method according to claim 1 , wherein the woman is after her menopause.

4 . The method according to claim 1 , wherein the non-hormonal drug is S-mirtazapine or a salt thereof, which is administered in an amount of 3 or 4.5 mg S-mirtazapine per day.

5 . The method according to claim 2 , wherein the woman is after her menopause.

6 . The method according to claim 2 , wherein the S-mirtazapine or a salt thereof is administered in an amount of 3 or 4.5 mg S-mirtazapine per day.

7 . The method according to claim 3 , wherein the non-hormonal drug is S-mirtazapine or a salt thereof, which is administered in an amount of 3 or 4.5 mg S-mirtazapine per day.

Assignments (3)
MERGER Recorded Dec 1, 2011
From: N.V. ORGANON
To: MSD OSS B.V.
Reel/Frame 027307/0482 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR PREVIOUSLY RECORDED ON REEL 019164 FRAME 0256. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNOR. Recorded Dec 11, 2007
From: BAKER, EDWARD; VAN DEN BERG, SIMON JOHANNES
To: N.V. ORGANON
Reel/Frame 020226/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2007
From: BAKER, EDWARD
To: N.V. ORGANON
Reel/Frame 019164/0256 →